HUNTINGDON VALLEY, Pa.--(BUSINESS WIRE)--June 12, 2006--Immunicon Corporation (NASDAQ-NM:IMMC - News) announced today that Pfizer, Inc. presented results from a drug development study, where an assay developed under contract with Pfizer was incorporated into the study design. The patients were enrolled by The Royal Marsden Hospital, London, England, and testing of circulating tumor cells (CTCs) was performed by Immunicon in its Pharma Services group. The data were presented by Gerhardt Attard, MD, MRCP from the Royal Marsden Hospital, London, UK, on June 4, 2006 at the 42nd Annual Meeting of the American Society of Clinical Oncology (ASCO), in Atlanta, Georgia.
